Neurocrine Biosciences Shares Purchased by Segall Bryant & Hamill

Institutional investor increases stake in biotech company

Published on Mar. 5, 2026

Got story updates? Submit your updates here. ›

Segall Bryant & Hamill LLC, an investment management firm, has increased its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 20.8% in the third quarter, according to a recent SEC filing. The firm now owns 54,474 shares of the company's stock, valued at approximately $7.6 million.

Why it matters

Neurocrine Biosciences is a prominent biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. The increase in Segall Bryant & Hamill's stake suggests confidence in the company's future prospects and pipeline.

The details

According to the SEC filing, Segall Bryant & Hamill purchased an additional 9,383 shares of Neurocrine Biosciences during the third quarter, bringing its total ownership to approximately 0.05% of the company's outstanding shares. The investment firm cited the company's strong product portfolio and pipeline as reasons for the increased investment.

  • Segall Bryant & Hamill's increased stake was reported in the firm's Q3 2026 13F filing with the SEC.

The players

Segall Bryant & Hamill LLC

An investment management firm that has increased its stake in Neurocrine Biosciences, Inc.

Neurocrine Biosciences, Inc.

A biopharmaceutical company focused on developing treatments for neurological, endocrine and neuropsychiatric disorders.

Got photos? Submit your photos here. ›

The takeaway

The increased investment by Segall Bryant & Hamill in Neurocrine Biosciences suggests that the institutional investor sees significant potential in the company's future growth and pipeline development, which could be a positive sign for the company's long-term prospects.